NCT02807636 · OUTCOME

Maximum Atezolizumab Serum Concentration

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma · Source last updated 2025-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: μg/ mL
Interval / dispersion: Standard Deviation
Time frame: Cycle 1 Day 1

What was measured

Maximum atezolizumab serum concentration.

Analysis population: The pharmacokinetic (PK)-evaluable population is defined as all participants dosed with atezolizumab who have at least one post-baseline PK result.

Groups in this outcome

Atezolizumab+Gemcitabine+Carboplatin/Cisplatin

Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

Atezolizumab Monotherapy

Eligible participants received open-label atezolizumab as monotherapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin	394
Atezolizumab Monotherapy	309

Reported measurements

Source class 1

Values in μg/ mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin	379	125	Not reported	Not reported	Not reported
Atezolizumab Monotherapy	390	129	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
125
value
379
group Id
OG001
spread
129
value
390

denoms

counts
group Id
OG000
value
394
group Id
OG001
value
309
units
Participants

description

Maximum atezolizumab serum concentration.

dispersion Type

Standard Deviation

groups

description
Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
id
OG000
title
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin
description
Eligible participants received open-label atezolizumab as monotherapy.
id
OG001
title
Atezolizumab Monotherapy

param Type

MEAN

population Description

The pharmacokinetic (PK)-evaluable population is defined as all participants dosed with atezolizumab who have at least one post-baseline PK result.

reporting Status

POSTED

time Frame

Cycle 1 Day 1

title

Maximum Atezolizumab Serum Concentration

type

SECONDARY

unit Of Measure

μg/ mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice